Skip to main content
Clinical Trials/NCT07257406
NCT07257406CompletedNot Applicable

The Use of Intravenous Dexamethasone for Post-operative Pain After Cesarean Delivery Under Neuraxial Anesthesia.

Valerie Zaphiratos1 site in 1 country87 target enrollmentStarted: September 13, 2018Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
87
Locations
1
Primary Endpoint
Visual Analog Pain Score (VAS) 6 hours post-operatively at first rise

Study Overview

Brief Summary

After surgery pain in women who have had a cesarean delivery is a determining factor in the quality and duration of their hospital stay. Insufficient pain relief can lead to longer hospitalization and long term pain, which can result in long term use of pain medication. A classic method to alleviate pain after cesarean delivery is by injecting morphine into the spinal fluid, in the women's back, in addition to prescribing morphine by mouth as needed after the surgery. However, the negative effects associated with morphine and morphine-like drugs, limit the doses used, their pain relief capacity, and can negatively affect the after surgical experience of women. An approach which uses pain relief that acts on different pain pathways to treat after surgery pain helps limit the negative effects of different drugs. The potential benefit of dexamethasone as pain relief in women who have had a cesarean delivery is all the more interesting because of its minimal negative effects compared to morphine-like drugs. Its low cost, its effectiveness to prevent nausea, and its impact on the general condition of patients make dexamethasone even more attractive.

Detailed Description

Postoperative pain in patients who have undergone a cesarean delivery is a determining factor in the quality and duration of their hospital stay. Suboptimal analgesia can lead to prolonged hospitalization and chronic pain, which can result in chronic use of pain medication. Treatment of post-operative pain after cesarean delivery uses intrathecal morphine, and the use of opioids as needed post-operatively. However, the side effects associated with opioids limit the doses used, their analgesic efficacy, and adversely affect the postoperative experience of patients. The multimodal approach to postoperative pain allows for analgesia that acts on different pain mechanisms while limiting the adverse effects of different drugs. The potential benefits of dexamethasone as a co-analgesic in women who have had a cesarean section are all the more interesting because of its minimal adverse effects compared to opioids. Its low cost, its effectiveness as antiemetic prophylaxis, and its impact on the general condition of patients make dexamethasone even more attractive.

In this randomised controlled trial, 100 patients are to be recruited and randomised to one of two groups. Both groups will receive standard treatment. In addition to standard treatment, the first group will receive dexamethasone 8 mg IV after umbilical cord clamping and the other group will receive a placebo.

The patients will be followed for 24 hours post-operatively. Their pain levels at rest and during movement will be recorded on an 11 point pain scale. The dose of hydromorphone used in the first 24 hours will be recorded. The patients are also asked to complete the QOR-40 questionnaire, which aims to assess the quality of their postoperative recovery. The primary outcome is the pain on an 11 point scale at the first rise 6 hours post-operatively.

The investigators hypothesize that dexamethasone will improve pain scores and diminish opioid use in the first 24 hours post-operatively.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Age ≥ 18 years
  • •Cesarean delivery
  • •Planned spinal or combined neuraxial anesthesia
  • •Presence of an investigator in the delivery room
  • •Pregnancy > 34 weeks gestation

Exclusion Criteria

  • •Cesarean delivery under general anesthesia
  • •Inability to understand French or English
  • •Allergy or hypersensitivity to dexamethasone
  • •Allergy to hydromorphone
  • •Allergy to NSAIDs
  • •Acute kidney injury or chronic kidney failure
  • •Preeclampsia
  • •Extremely urgent cesarean section
  • •Urgent cesarean section with non-reassuring fetal monitoring
  • •Known maternal heart disease
  • •High-grade placental abnormality
  • •Diabetes (pregnancy or pre-existing)
  • •Systemic infection, sepsis, fever
  • •Regular use of dexamethasone in the last year
  • •Weight greater than 120 kg and less than 70 kg
  • •Height less than 150 cm
  • •Chronic pain and/or chronic use of opioids

Arms & Interventions

Placebo

Placebo Comparator

Participants who receive 0.9% saline IV (2 ml) 5 min after cord clamping.

Intervention: Placebo (Drug)

Dexamethasone

Active Comparator

Participants who receive dexamethasone 8 mg IV (2 ml) 5 min after cord clamping.

Intervention: Dexamethasone (IV) (Drug)

Outcomes

Primary Outcomes

Visual Analog Pain Score (VAS) 6 hours post-operatively at first rise

Time Frame: 6 hours post-operatively

Visual Analog Pain Score (VAS), from 0 to 10, when patients first stand out of bed 6 hours post-operatively. A score of 0 on 10 being no pain, and a score of 10 on 10 being the worst pain imaginable.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Valerie Zaphiratos
Sponsor Class
Other
Responsible Party
Sponsor Investigator
Principal Investigator

Valerie Zaphiratos

Associate Professor of Anesthesiology

St. Justine's Hospital

Study Sites (1)

Loading locations...

Similar Trials